TMCI Dec 2024 2.500 call
| Previous close | 3.5000 |
| Open | 3.3000 |
| Bid | 2.9000 |
| Ask | 3.9000 |
| Strike | 2.50 |
| Expiry date | 2024-12-20 |
| Day's range | 3.3000 - 3.3000 |
| Contract range | N/A |
| Volume | |
| Open interest | 27 |
GlobeNewswireTreace to Present at Truist Securities MedTech Conference
Tuesday, June 18, 2024 at 8:00 am Eastern TimePONTE VEDRA, Fla., May 28, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fireside
GuruFocus.comDirector Jane Kiernan Acquires 19,356 Shares of Treace Medical Concepts Inc (TMCI)
On May 14, 2024, Director Jane Kiernan purchased 19,356 shares of Treace Medical Concepts Inc (NASDAQ:TMCI), as reported in the SEC Filing.
GuruFocus.comDirector Deepti Jain Acquires 25,000 Shares of Treace Medical Concepts Inc (TMCI)
On May 10, 2024, Deepti Jain, Director at Treace Medical Concepts Inc (NASDAQ:TMCI), purchased 25,000 shares of the company, as reported in a recent SEC Filing.
